The development of a CDK2-docking site peptide that inhibits p53 and sensitizes cells to death.

Abstract excerpt

Cyclin-dependent protein kinases play important roles in cell cycle progression and are attractive targets for the design of anti-proliferative drugs. Two distinct synthetic CDK1/2 inhibitors, Roscovitine and NU2058, are pharmacologically distinct in their ability to modify p53-dependent transcription and perturb cell cycle progression. Although such active-site CDK1/2 inhibitors comprise the most standard type...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Cyclin A
• Share to CDC2-CDC28 Kinases